Latest Articles

Publication Date
All News Scientific
Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha - Targeting ADC at AACR Annual Meeting 2026 - riauone.com

Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha - Targeting ADC at AACR Annual Meeting 2026 riauone.com

Published: April 24, 2026, 4:01 a.m.
Read Full Article
Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026 - The Manila Times

Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026 The Manila Times

Published: April 21, 2026, 9:40 p.m.
Read Full Article
HerAnova Commercializes Blood Test for Endometriosis Detection, Targeting Years-Long Diagnostic Delays - R&D World

HerAnova Commercializes Blood Test for Endometriosis Detection, Targeting Years-Long Diagnostic Delays R&D World

Published: March 16, 2026, 9:31 p.m.
Read Full Article
ABSI: ABS-201 advances in AGA and endometriosis, targeting major markets with key data due by 2027 - TradingView

ABSI: ABS-201 advances in AGA and endometriosis, targeting major markets with key data due by 2027 TradingView

Published: March 9, 2026, 2:54 p.m.
Read Full Article
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 - Sahm

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 …

Published: Jan. 9, 2026, 6:18 a.m.
Read Full Article
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 - The Manila Times

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 …

Published: Jan. 8, 2026, 12:53 p.m.
Read Full Article
Targeting DPP4: Ferroptosis and Endometrial Receptivity in PCOS - BIOENGINEER.ORG

Targeting DPP4: Ferroptosis and Endometrial Receptivity in PCOS BIOENGINEER.ORG

Published: Dec. 23, 2025, 7:31 p.m.
Read Full Article
Targeting DPP4: Ferroptosis and Endometrial Receptivity in PCOS - Bioengineer.org

Targeting DPP4: Ferroptosis and Endometrial Receptivity in PCOS Bioengineer.org

Published: Dec. 23, 2025, 7:31 p.m.
Read Full Article
Dual Targeting of Orphan Nuclear Receptors NR4A1 and NR4A2 for Nonhormonal Endometriosis Therapy - Endocrine Society

Dual Targeting of Orphan Nuclear Receptors NR4A1 and NR4A2 for Nonhormonal Endometriosis Therapy Endocrine Society

Published: Nov. 18, 2025, 9:22 a.m.
Read Full Article
Cyclana Bio Raises £5M to Reverse Endometriosis Through Extracellular Matrix Targeting - Femtech Insider

Cyclana Bio Raises £5M to Reverse Endometriosis Through Extracellular Matrix Targeting Femtech Insider

Published: Oct. 20, 2025, 8:02 a.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!